Biodesix Statistics
Total Valuation
Biodesix has a market cap or net worth of $176.74 million. The enterprise value is $204.20 million.
Important Dates
The last earnings date was Friday, November 1, 2024, before market open.
| Earnings Date | Nov 1, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Biodesix has 145.47 million shares outstanding. The number of shares has increased by 57.83% in one year.
| Current Share Class | 145.47M |
| Shares Outstanding | 145.47M |
| Shares Change (YoY) | +57.83% |
| Shares Change (QoQ) | +15.04% |
| Owned by Insiders (%) | 47.37% |
| Owned by Institutions (%) | 31.34% |
| Float | 66.39M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 2.10 |
| Forward PS | 2.18 |
| PB Ratio | 6.21 |
| P/TBV Ratio | 27.78 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 3.11 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.40, with a Debt / Equity ratio of 2.24.
| Current Ratio | 3.40 |
| Quick Ratio | 3.04 |
| Debt / Equity | 2.24 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -3.91 |
Financial Efficiency
Return on equity (ROE) is -331.82% and return on invested capital (ROIC) is -30.74%.
| Return on Equity (ROE) | -331.82% |
| Return on Assets (ROA) | -22.79% |
| Return on Capital (ROIC) | -30.74% |
| Revenue Per Employee | $302,129 |
| Profits Per Employee | -$201,931 |
| Employee Count | 217 |
| Asset Turnover | 0.69 |
| Inventory Turnover | 11.68 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -15.49% in the last 52 weeks. The beta is 1.21, so Biodesix's price volatility has been higher than the market average.
| Beta (5Y) | 1.21 |
| 52-Week Price Change | -15.49% |
| 50-Day Moving Average | 1.58 |
| 200-Day Moving Average | 1.56 |
| Relative Strength Index (RSI) | 28.77 |
| Average Volume (20 Days) | 713,840 |
Short Selling Information
The latest short interest is 415,740, so 0.29% of the outstanding shares have been sold short.
| Short Interest | 415,740 |
| Short Previous Month | 415,133 |
| Short % of Shares Out | 0.29% |
| Short % of Float | 0.63% |
| Short Ratio (days to cover) | 2.72 |
Income Statement
In the last 12 months, Biodesix had revenue of $65.56 million and -$43.82 million in losses. Loss per share was -$0.38.
| Revenue | 65.56M |
| Gross Profit | 50.96M |
| Operating Income | -34.56M |
| Pretax Income | -44.51M |
| Net Income | -43.82M |
| EBITDA | -29.26M |
| EBIT | -34.56M |
| Loss Per Share | -$0.38 |
Full Income StatementBalance Sheet
The company has $31.41 million in cash and $62.50 million in debt, giving a net cash position of -$31.09 million or -$0.21 per share.
| Cash & Cash Equivalents | 31.41M |
| Total Debt | 62.50M |
| Net Cash | -31.09M |
| Net Cash Per Share | -$0.21 |
| Equity (Book Value) | 27.86M |
| Book Value Per Share | 0.19 |
| Working Capital | 31.05M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$56.84 million and capital expenditures -$5.38 million, giving a free cash flow of -$62.21 million.
| Operating Cash Flow | -56.84M |
| Capital Expenditures | -5.38M |
| Free Cash Flow | -62.21M |
| FCF Per Share | -$0.43 |
Full Cash Flow StatementMargins
Gross margin is 77.72%, with operating and profit margins of -52.71% and -66.84%.
| Gross Margin | 77.72% |
| Operating Margin | -52.71% |
| Pretax Margin | -66.84% |
| Profit Margin | -66.84% |
| EBITDA Margin | -44.63% |
| EBIT Margin | -52.71% |
| FCF Margin | -100.42% |
Dividends & Yields
Biodesix does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -57.83% |
| Shareholder Yield | -57.83% |
| Earnings Yield | -24.69% |
| FCF Yield | -35.05% |
Analyst Forecast
The average price target for Biodesix is $3.08, which is 153.50% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $3.08 |
| Price Target Difference | 153.50% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 4 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsStock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Biodesix has an Altman Z-Score of -4.85 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -4.85 |
| Piotroski F-Score | 3 |